Drug discovery company Nimbus Therapeutics has partnered with Eli Lilly to develop a novel oral treatment for obesity and other metabolic diseases. The companies aim to apply Nimbus’ computational chemistry and structure-based drug design approach to an early-stage, small molecule discovery programme addressing a significant unmet need in obesity. This latest collaboration follows a previous partnership between […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!